novartis glp-1 glp 1 GlaxoSmithKline Recalls Antihypertensive Drug Made at Novartis Facility GLP-1 use tripled among non-diabetics,
Description
doi: 10.7759/CUREUS.66280 58 MeierJJMengeBASchenkerNErdmannSKahle-StephanMSchliessFet al
Celebrity and public figure disclosures normalized conversations about prescription weight management
These trials studied semaglutide 2.4mg weekly in people with obesity or overweight with weight-related conditionsthe exact population seeking medication for weight loss without diabetes
In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July
[DOI] [PMC free article] [PubMed] [Google Scholar] 36.Yarchoan M, et al
Speak to a provider and get expert guidance tailored to your weight loss goals
